{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Percentage of patients who have received at least one dose of pembrolizumab and have responded (and have completed imaging requirement). Overall response rate is defined as the proportion of participants with a best overall response of CR or PR as defined by RECIST 1.1","groups":[{"description":"* Metastatic platinum-resistant or refractory OvC previously treated with ≥1 line of prior platinum-containing therapy\n* Galinpepimut-S + Montanide + GM-CSF + pembrolizumab","id":"OG000","title":"Ovarian Cancer (OvC)"},{"description":"One subject enrolled but discontinued before efficacy can be assessed. For this reason, this subject was not included in the evaluation for efficacy or safety.","id":"OG001","title":"Colorectal Cancer"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who have received at least one dose of pembrolizumab (mITT population).\n\nPatients only enrolled in the Ovarian Cancer (OvC) arm. One subject from the Colorectal Cancer (CRC) arm enrolled but discontinued before efficacy can be assessed. The other arms/groups were removed from this study.","reportingStatus":"POSTED","timeFrame":"33 months","title":"Overall Response Rate (ORR) - Overall Response Rate","type":"PRIMARY","unitOfMeasure":"Participants"}